دورية أكاديمية
Rotavirus Vaccine Effectiveness Against Severe Acute Gastroenteritis: 2009-2022.
| العنوان: | Rotavirus Vaccine Effectiveness Against Severe Acute Gastroenteritis: 2009-2022. |
|---|---|
| المؤلفون: | Diallo AO; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia., Wikswo ME; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia., Sulemana I; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia., Sahni LC; Texas Children's Hospital and Baylor College of Medicine, Houston, Texas., Boom JA; Texas Children's Hospital and Baylor College of Medicine, Houston, Texas., Ramani S; Texas Children's Hospital and Baylor College of Medicine, Houston, Texas., Selvarangan R; Division of Infectious Diseases, Children's Mercy, Kansas City, Missouri., Moffatt ME; Division of Infectious Diseases, Children's Mercy, Kansas City, Missouri., Harrison CJ; Division of Infectious Diseases, Children's Mercy, Kansas City, Missouri., Halasa N; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee., Chappell J; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee., Stewart L; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee., Staat MA; Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio., Schlaudecker E; Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio., Quigley C; Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio., Klein EJ; Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, Washington., Englund JA; Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, Washington., Zerr DM; Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, Washington., Weinberg GA; University of Rochester School of Medicine and Dentistry and UR-Golisano Children's Hospital, Rochester New York., Szilagyi PG; University of Rochester School of Medicine and Dentistry and UR-Golisano Children's Hospital, Rochester New York., Albertin C; University of Rochester School of Medicine and Dentistry and UR-Golisano Children's Hospital, Rochester New York., Johnston SH; Department of Pediatrics, University of California at San Francisco, Benioff Children's Hospital Oakland, Oakland, California; and., Williams JV; Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Michaels MG; Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Hickey RW; Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Curns AT; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia., Honeywood M; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia., Mijatovic-Rustempasic S; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia., Esona MD; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia., Bowen MD; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia., Parashar UD; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia., Gautam R; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia., Mirza SA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia., Tate JE; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. |
| المصدر: | Pediatrics [Pediatrics] 2024 Sep 10. Date of Electronic Publication: 2024 Sep 10. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Academy of Pediatrics Country of Publication: United States NLM ID: 0376422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-4275 (Electronic) Linking ISSN: 00314005 NLM ISO Abbreviation: Pediatrics Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Elk Grove Village Il : American Academy of Pediatrics Original Publication: Springfield, Ill., Thomas. |
| مستخلص: | Background: Rotavirus was the leading cause of acute gastroenteritis among US children until vaccine introduction in 2006, after which, substantial declines in severe rotavirus disease occurred. We evaluated rotavirus vaccine effectiveness (VE) over 13 years (2009-2022). Methods: We analyzed data from the New Vaccine Surveillance Network using a test-negative case-control design to estimate rotavirus VE against laboratory-confirmed rotavirus infections among children seeking care for acute gastroenteritis (≥3 diarrhea or ≥1 vomiting episodes within 24 hours) in the emergency department (ED) or hospital. Case-patients and control-patients were children whose stool specimens tested rotavirus positive or negative, respectively, by enzyme immunoassay or polymerase chain reaction assays. VE was calculated as (1-adjusted odds ratio)×100%. Adjusted odds ratios were calculated by multivariable unconditional logistic regression. Results: Among 16 188 enrolled children age 8 to 59 months, 1720 (11%) tested positive for rotavirus. Case-patients were less often vaccinated against rotavirus than control-patients (62% versus 88%). VE for receiving ≥1 dose against rotavirus-associated ED visits or hospitalization was 78% (95% confidence interval [CI] 75%-80%). Stratifying by a modified Vesikari Severity Score, VE was 59% (95% CI 49%-67%), 80% (95% CI 77%-83%), and 94% (95% CI 90%-97%) against mild, moderately severe, and very severe disease, respectively. Rotavirus vaccines conferred protection against common circulating genotypes (G1P[8], G2P[4], G3P[8], G9P[8], and G12[P8]). VE was higher in children <3 years (73% to 88%); protection decreased as age increased. Conclusions: Rotavirus vaccines remain highly effective in preventing ED visits and hospitalizations in US children. Competing Interests: CONFLICT OF INTEREST DISCLOSURES: Dr Weinberg has research support from the New York State Department of Health AIDS Institute and has received honoraria from Merck and Inhalon Biopharma; Dr Englund has research support from AstraZeneca, Merck, Pfizer, and GlaxoSmithKline and consults for AstraZeneca, GlaxoSmithKline, Pfizer, and Sanofi Pasteur; Dr Halasa has research support from Sanofi Pasteur and Quidel and an education grant from Genetech; Dr Harrison received honoraria from WebMD, and his institution received funding for research for in which he was an investigator from GSK, Merck, and Pfizer up to July 1, 2022; Dr Staat has research support from the National Institutes of Health, Merck, Pfizer, and Cepheid and has received honoraria from UpToDate; Dr Schlaudecker has research support from the National Institutes of Health and Pfizer and has received honoraria from Sanofi Pasteur; Dr Zerr received research support from Merck and honoraria from UpToDate and served as a consultant for AlloVir; and the other authors have no conflicts of interest relevant to this article to disclose. (Copyright © 2024 by the American Academy of Pediatrics.) |
| تواريخ الأحداث: | Date Created: 20240910 Latest Revision: 20240910 |
| رمز التحديث: | 20240910 |
| DOI: | 10.1542/peds.2024-066879 |
| PMID: | 39252660 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1098-4275 |
|---|---|
| DOI: | 10.1542/peds.2024-066879 |